Callan Family Office LLC Purchases 63,300 Shares of Gilead Sciences, Inc. $GILD

Callan Family Office LLC increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 239.4% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 89,738 shares of the biopharmaceutical company’s stock after acquiring an additional 63,300 shares during the period. Callan Family Office LLC’s holdings in Gilead Sciences were worth $9,949,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in GILD. Price T Rowe Associates Inc. MD grew its position in shares of Gilead Sciences by 314.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after buying an additional 11,156,382 shares during the last quarter. Nuveen LLC bought a new stake in shares of Gilead Sciences during the 1st quarter valued at about $620,415,000. Kingstone Capital Partners Texas LLC acquired a new position in Gilead Sciences during the 2nd quarter worth approximately $238,083,000. Los Angeles Capital Management LLC raised its stake in Gilead Sciences by 422.6% during the 1st quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company’s stock worth $282,706,000 after buying an additional 2,040,261 shares during the period. Finally, Vanguard Group Inc. raised its stake in Gilead Sciences by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock worth $13,162,606,000 after buying an additional 1,942,433 shares during the period. Institutional investors own 83.67% of the company’s stock.

Insiders Place Their Bets

In related news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the completion of the transaction, the insider directly owned 114,168 shares in the company, valued at $13,532,333.04. The trade was a 19.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $109.74, for a total value of $548,700.00. Following the transaction, the director owned 8,920 shares of the company’s stock, valued at approximately $978,880.80. The trade was a 35.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 82,000 shares of company stock valued at $9,402,130 in the last ninety days. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $116.74 on Friday. The stock has a market cap of $144.85 billion, a PE ratio of 23.26, a price-to-earnings-growth ratio of 0.80 and a beta of 0.34. Gilead Sciences, Inc. has a fifty-two week low of $84.17 and a fifty-two week high of $121.83. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The stock has a fifty day moving average of $114.57 and a 200-day moving average of $110.19.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company had revenue of $7.08 billion during the quarter, compared to analysts’ expectations of $6.95 billion. During the same period in the previous year, the business earned $2.01 earnings per share. The firm’s quarterly revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.7%. The ex-dividend date was Monday, September 15th. Gilead Sciences’s payout ratio is presently 62.95%.

Analyst Ratings Changes

Several brokerages have recently commented on GILD. Citigroup increased their price objective on Gilead Sciences from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Wednesday. Royal Bank Of Canada increased their price target on Gilead Sciences from $98.00 to $100.00 and gave the company a “sector perform” rating in a research report on Wednesday. Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. JPMorgan Chase & Co. increased their price target on Gilead Sciences from $135.00 to $145.00 and gave the company an “overweight” rating in a research report on Tuesday, September 16th. Finally, Cantor Fitzgerald raised their target price on Gilead Sciences from $129.00 to $135.00 and gave the stock an “overweight” rating in a research report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $118.08.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.